Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: Median survival was 12 weeks, 8 weeks after radiotherapy alone, 16 weeks after combined modality treatment. 14 patients died from disease. Eleven patients (68%) experienced regression of their neurological symptoms during or soon after completion of radiotherapy. Seven patients regained their ability to walk, six had pain reduction, three regression of bladder and bowel incontinence. In three patients symptom progression and in two patients no change occurred. Side effects were: myelosuppression (CTC) Grade I: n = 2, Grade II: n = 4, Grade III: n = 4 patients and Grade IV: n = 1. Nine patients had dysphagia, seven mucositis, three suffered from nausea. No late toxicity was observed. CONCLUSION:
|
Authors | B Hermann, B Hültenschmidt, M L Sautter-Bihl |
Journal | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
(Strahlenther Onkol)
Vol. 177
Issue 4
Pg. 195-9
(Apr 2001)
ISSN: 0179-7158 [Print] Germany |
PMID | 11370554
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Brain
(drug effects, pathology)
- Carcinoma
(radiotherapy, secondary)
- Combined Modality Therapy
- Feasibility Studies
- Female
- Humans
- Magnetic Resonance Imaging
- Male
- Meningeal Neoplasms
(radiotherapy, secondary)
- Middle Aged
- Palliative Care
(methods)
- Radiotherapy, Adjuvant
- Retrospective Studies
- Spine
(drug effects, pathology)
- Survival Analysis
- Treatment Outcome
|